Eli Lilly and Company became the first healthcare firm to reach a $1 trillion market valuation on November 21, 2025. The milestone followed continued revenue growth supported by demand for diabetes and immunology therapies and recently commercialized treatments. Market reports indicated elevated sales volumes for the company’s obesity drug portfolio, which contributed materially to its latest financial results.